In December 2021, Sun Pharmaceutical Industries announced that one of its wholly-owned subsidiaries has obtained final approval from the U.S. FDA for its abbreviated new drug application (ANDA) for generic Amphotericin B Liposome for Injection, available in a single-dose vial of 50 mg. This approval for the generic product is based on AmBisome Liposome for Injection, also in a 50 mg/vial, as the reference product
Frequently Asked Questions
The market is segmented based on Segmentation, By Anatomy (Lung, Bones, Central Nervous System and Others), Treatment (Amphotericin B, Azoles, Surgery, and Others), Dosage (Tablet, Injection, Capsule, and Others), Route of Administration (Intravenous, Oral, and Others), Diagnosis (Chest CT Scan, Chest X-ray, Skin Biopsy, Sputum Culture and Examination, Urinary Antigen Detection, Urine culture, and Others), End-Users (Clinic, Hospital, and Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) – Industry Trends and Forecast to 2031
.
The Global Blastomycosis Treatment Market size was valued at USD 201.70 USD Million in 2023.
The Global Blastomycosis Treatment Market is projected to grow at a CAGR of 6.1% during the forecast period of 2024 to 2031.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
